1473-CARM1 Inhibition: Enhancing Cancer Immunotherapy

This research article identifies the CARM1 epigenetic enzyme as a primary negative regulator of cDC1 dendritic cells, which are essential for initiating anti-tumor immunity. The authors demonstrate that inactivating the Carm1 gene or using a small-molecule inhibitor significantly improves the ability of these cells to cross-present cancer antigens to cytotoxic T cells. Mechanistically, CARM1 expression is triggered by the immunosuppressive cytokine TGFβ, which limits the chromatin accessibility of genetic pathways required for dendritic cell activation. By removing this barrier, the researchers observed increased T cell infiltration and enhanced effectiveness of PD-1 blockade in treating resistant tumors. These findings suggest that targeting CARM1 could be a viable therapeutic strategy to turn "cold" tumors into "hot" ones by restoring the cancer-immunity cycle.References:Zhang X, Xirenayi S, Zhao Y, et al. The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity[J]. Science, 2026, 393(6807): eaea1200.前往小宇宙评论区与主播互动